ClinicalTrials.gg
Drug

Exatecan clinical trials

studies test it
15
open now
0
in phase 3
1
first study started
1999

How each study uses exatecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

exatecan mesylate
15

Studies by the year they started

15 studies that test it; most in 1999 (7)

Studies that test exatecan, by start year
YearStudies
19997
20002
20012
20022
20032

Who runs them

Industry 13 · Other 2

Daiichi Sankyo (12) · Daiichi Pharmaceuticals (1) · Jonsson Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)

Often tested with

Tested in the same studies.

Gemcitabine (1)

Studies

Open first, then newest update. How each study uses exatecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Codes

What other systems call exatecan · ClinicalTrials.gg INT003870

  • MeSH (NLM) C095887exatecanConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) OC71PP0F89EXATECANConfirmed FDA, NLM, Wikidata
  • Wikidata Q5419343exatecanConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66720ExatecanOne source FDA
  • DrugBank DB12185One source Wikidata

Also registered as exatecan mesylate (UNII D2VJ1CC26Q).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.